Drug Profile
Carbon-11 UCB-J - Rodin Therapeutics/UCB Biopharma
Alternative Names: (11)C-UCB-J - Rodin Therapeutics/UCB Biopharma; SV2A PET radiotracer - Rodin Therapeutics/UCB BiopharmaLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator UCB Biopharma
- Developer Rodin Therapeutics
- Class Fluorobenzenes; Imaging agents; Pyridines; Pyrrolidinones; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Netherlands (IV, Injection)
- 25 Jan 2021 Yale University plans a clinical trial for Cocaine related disorders (Diagnosis) in June 2021 (IV) (NCT04721418)
- 23 Mar 2020 Stanford University plans a phase I trial for Major depressive disorder (Diagnosis, In volunteers) in USA (IV) in December 2020 (NCT04311619)